CANVAS Study	Canagliflozin Cardiovascular Assessment Study
CREDENCE Study	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
DAPA-CKD Study	Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Study
DAPA-HF Study	Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Study
E-LIFT Study	EndoBarrier(R) in Diabetes Trial
EMPEROR-Preserved Study	EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure with Preserved Ejection Fraction
EMPEROR-Reduced Study	EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure with Reduced Ejection Fraction
ENLIVEN Study	Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subject with Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
ESSENTIAL Study	Efficacy and Safety of Sparsentan in Patients with IgA Nephropathy
FALCON program	Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
FASCINATE–1 Study	TVB-2640 (FASN inhibitor) for the Treatment of Nonalcoholic Steatohepatitis
GRAECE Study	Greek Atorvastatin and Coronary-heart-disease Evaluation Study
LEAN Study	The Liraglutide Efficacy and Action in NASH
LUBIPRONE Study	Efficacy, safety, and tolerability of lubiprostone for the treatment of nonalcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomized, placebo-controlled study design
MIRNA Study	Metabolic Interventions to Resolve NASH with fibrosis
MOMENTUM Obesity Trials	Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Studies Evaluating the Safety and Efficacy of Investigational Agents in Obese or Overweight Adult Participants
PIVENS Trial	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
SURPASS-3 MRI Study	Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomized, open-label, parallel-group, phase 3 SURPASS-3 trial
SURPASS-3 Trial	Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial
SYNERGY-NAS Trial	A Study of Tirzepatide (LY3298176) in Participants with Nonalcoholic Steatohepatitis (NASH)